Application of bayes theorem to aminoglycoside-associated nephrotoxicity: Comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing

Journal of Clinical Pharmacology

Volumn 44, Issue 7, 2004, Pages 696-707

  Kim, Myong Jin ^a,b   Bertino Jr , Joseph S ^a,b   Erb, Tara A ^b   Jenkins, Paul L ^b   Nafziger, Anne N ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

Author keywords

Aminoglycoside associated nephrotoxicity; Bayes factors; Bayes theorem; Extended interval dosing; Multiple daily dosing

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPHOTERICIN B; AMPICILLIN; CEFALOTIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; FUROSEMIDE; GENTAMICIN; METICILLIN; NAFCILLIN; NETILMICIN; PENICILLIN G; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BAYES THEOREM; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MONITORING; EXTENDED INTERVAL DOSING; FOLLOW UP; HUMAN; INCIDENCE; INDIVIDUALIZATION; MATHEMATICAL ANALYSIS; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MULTIPLE DRUG DOSE; NEPHROTOXICITY; PROBABILITY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; SCORING SYSTEM; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; BAYES THEOREM; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 2942694448     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266633     Document Type: Review

References (69)

1. Goodman SN: Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med 1999;130:1005-1013.
2. Kadane JB: Prime time for Bayes. Controlled Clin Trials 1995;16:313-318.
3. Bennett WM: Mechanisms of aminoglycoside nephrotoxicity. Clin Exper Pharmacol Physiol 1989;16:1-6.
4. Paterson DL, Robson JMB, Wagener MM: Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998;13:735-739.
5. Garamycin (gentamicin), in: Physicians' Desk Reference. Montvale, NJ: Medical Economics, 1997;2632-2635.
6. Gilbert DN: Editorial response: meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin Infect Dis 1997;24:816-819.
7. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R: Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995;39:650-655.
8. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL: Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43:1549-1555.
9. Koo J, Tight R, Rajkumar V, Hawa Z: Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med 1996;101:177-183.
10. Gonzalez P, Aguado JA, Martin MA, Fernandez-Chacon T, Ortuno B: Once-daily aminoglycoside dosing [letter, comment]. Lancet 1993;341:895.
11. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN: Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993;167:173-179.
12. van Lent-Evers NAEM, Mathot RAA, Geus WP, van Hout BA, Vinks AATMM: Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999;21:63-73.
13. Streetman DS, Nafziger AN, Destache CJ, Bertino JS Jr: Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmaco-therapy 2001;21(4):443-451.
14. Karachalios GN, Houpas P, Tziviskou E, et al: Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections. Int J Clin Pharmacol Ther 1998; 36:561-564.
15. Gilbert DN, Lee BL, Dworkin RJ, et al: A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am J Med 1998;105:182-191.
16. Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ: Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999;19:1252-1260.
17. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P: Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-339.
18. Sturm AW: Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989; 159:931-937.
19. ter Braak EW, de Vries PJ, Bouter KP, et al: Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990;89:58-66.
20. Nordstrom L, Ringberg H, Cronberg S, Tjernstrom O, Walder M: Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-173.
21. Gill MA, Cheetham TC, Chenella FC, et al: Matched case-control study of adjusted versus nonadjusted gentamicin dosing in perforated and gangrenous appendicitis. Ther Drug Monit 1986;8:451-456.
22. Leehey DJ, Braun BI, Tholl DA, et al: Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrl 1993;4:81-90.
23. McGrath BJ, Kang SL, Ruffing MJ, Lerner SA, Rybak MJ: A double-blind comparison of once-daily dosing of aminoglycosides versus twice-daily dosing. Programs and abstracts, 35th interscience conference on antimicrobial agents and chemotherapy. September 1995.
24. Abbruzzese JL, Rocco LE, Laskin OL, Skubitz KM, McGaughey MD, Lipsky JJ: Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections. Am J Med 1983;74:694-699.
25. Labovitz E, Levison ME, Kaye D: Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974;6:465-470.
26. Smith CR, Baughman KL, Edwards CQ, Rogers JF, Lietman PS: Controlled comparison of amikacin and gentamicin. N Engl J Med 1977;296:349-353.
27. Smith CR, Lipsky JJ, Laskin OL, et al: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980;302:1106-1109.
28. Appet GB: Aminoglycoside nephrotoxicity. Am J Med 1990;88:16S-20S.
29. Rotschafer JC, Rybak MJ: Single daily dosing of aminoglycosides: a commentary. Ann Pharmacother 1994;28:797-801.
30. Meyer RD: Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Aro J Med 1986;80:119-125.
31. Burkle WS: Is tobramycin less nephrotoxic than gentamicin? Clin Pharm 1986;5:514-516.
32. Pancorbo S, Compty C, Heissler J: Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized-pharmacokinetic dosing regimens. Biopharm Drug Dispos 1982:3: 83-88.
33. Bertino JS Jr: Measured versus estimated creatinine clearance in patients with low serum creatinine values. Ann Pharmacother 1993; 27:1439-1442.
34. Eisenberg JM, Koffer H, Glick HA, et al: What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107:900-909.
35. Smith CR, Lietman PS: Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans. Antimicrob Agents Chemother 1983;23:133-137.
36. Moore RD, Lerner SA, Levine DP: Nephrotoxicity of aztreonam versus aminoglycoside therapy in serious ill nonneutropenic patients. J Infect Dis 1992;165:683-688.
37. Gatell JM, SanMiguel JG, Zamora L, et al: Tobramycin and amikacin nephrotoxicity: value of serum creatinine versus urinary concentration of beta-2-microglobulin. Nephron 1985;41:337-343.
38. Cabrera J, Arroyo V, Ballesta AM, et al: Aminoglycoside nephrotoxicity in cirrhosis: value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982;82:97-105.
39. Felisart J, Rimola A, Arroyo V, et al: Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985;5:457-462.
40. Zaske DE, Shikuma LR, Tholl DA: Antibiotics and other anti-infective agents: aminoglycosides, in: Taylor WJ, Caviness MH (eds.), A Textbook for the Clinical Application of Therapeutic Drug Monitoring. Abbott Park, IL: Abbott Laboratories, 1986;285-320.
41. Ferriols-Lisart R, Alos-Alminana M: Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health-Syst Pharm 1996;53:1141-1150.
42. Hatala R, Dinh T, Cook DJ: Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124:717-725.
43. Munckhof WJ, Grayson ML, Turnidge JD: A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996;37:645-663.
44. Barza M, Ioannidis JPA, Cappelleri JC, Lau J: Single or multiple daily doses of aminoglycosides: a meta-analysis. Br Med J 1996;312: 338-345.
45. Galloe AM, Graudal N, Christensen HR, Kampmann JP: Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995;48:39-43.
46. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC: A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-795.
47. Ali MZ, Goetz MB: A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:796-809.
48. Freeman CD, Straver AH: Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy 1996;16:1093-1020.
49. Chuck SK, Raber SR, Rodvold KA, Areff D: National survey of extended-interval aminoglycoside dosing Clin Infect Dis 2000; 30:433-439.
50. Burton ME, Ash CL, Hill DP, Handy T, Shepherd MD, Vasko MR: A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration. Clin Pharmacol Ther 1991;49:685-694.
51. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH: Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39:677-686.
52. Lerner AM, Reyes MP, Cone LA, et al: Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983;1:1123-1126.
53. German and Austrian Imipenem/Cilastatin Study Group. Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life threatening infections. Eur J Clin Microbial Infect Dis 1992;11:683-692.
54. Gatell JM, SanMiguel JG, Araujo V, et al: Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin. Antimicrob Agents Chemother 1984;26: 766-769.
55. Gatell JM, SanMiguel JG, Zamora L, et al: Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin. Antimicrob Agents Chemother 1983;23:897-901.
56. Smith CR, Ambinder R, Lipsky JJ, et al: Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. Ann Intern Med 1984;101:469-477.
57. Kepczyk T, Ryan PJ III, McAllister K, Otraje J: The absence of nephrotoxicity and differential nephrotoxicity between tobramycin and gentamicin. South Med J 1990;83:1149-1152.
58. Hoepelman AIM, Bakker LJ, Verhoef J: Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections. Antimicrob Agents Chemother 1988;32:473-476.
59. Plant ME, Schentag JJ, Jusko WJ: Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients. J Med 1979;10:257-266.
60. Smith CR, Lipsky JJ, Lietman PS: Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Antimicrob Agents Chemother 1979;15:780-782.
61. Smith CR, Maxwell RR, Edwards CQ, Rogers JF, Lietman PS: Nephrotoxicity induced by gentamicin and amikacin. Johns Hopkins Med J 1978;142:85-90.
62. Hoepelman IM, Rozenberg-Arska M, Verhoef J: Comparison of once daily ceftriaxone with gentamicin plus cefuroxime for treatment of serious bacterial infections. Lancet 1988;1:1305-1309.
63. Baciewicz AM, Sokos DR, Cowan RI: Aminoglycoside-associated nephrotoxicity in the elderly. Ann Pharmacother 2003;37(2):182-186.
64. Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P: Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996;40:2494-2499.
65. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P: Once-daily gentamicin versus once-daily netilmicin in patients with serious infections: a randomized clinical trial. J Antimicrob Chemother 1994;33:823-835.
66. Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM: Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. Q J Med 2002;95(5):291-297.
67. Matzke GR, Lucarotti RL, Shapiro HS: Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol 1983;3: 11-17.
68. Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS Jr: Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999;43:623-629.
69. Williams PJ, Hull JH, Sarubbi FA, Rogers JF, Wargin WA: Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. J CIin Pharmacol 1986;26:79-86.